We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CareFusion Warned Over Handling of Debris and Particulate Matter

CareFusion Warned Over Handling of Debris and Particulate Matter

August 8, 2014

CareFusion received an FDA warning letter for failing to analyze debris and particulate matter on its shunts and inside peritoneal catheters and tubing.

The company’s corrective and preventive action investigation should have identified the material and determined its source, according to the June 6 letter posted online.

The devicemaker was aware of complaints about debris and particulate matter with its Denver Ascites Shunt and Percutaneous Access Kit with Ascites Shunt since August 2011, the letter says. The Vernon Hills, Ill., facility, which operates as a specification developer and complaint file establishment, opened a CAPA on Aug. 1, 2013, and closed it on Aug. 23.

According to the warning letter, CareFusion had received 32 complaints about particulate matter or debris since August 2011. An FDA review of 10 of those complaints found that they all contained the language: “A review of complaint data identified a previous complaint with a similar failure mode. Review of the previous complaint investigation noted corrective actions including remedial training and improved CME (controlled manufacturing environment) requirements were implemented for the previous complaint.”

However, CareFusion “could not locate the ‘previous complaint’ or associated complaint investigation and corrective actions referenced in the 10 reviewed complaint investigations,” the letter says. The FDA said it would assess the company’s corrective action on this issue during a follow-up inspection.

Additional citations related to supplier screening. For example, CareFusion’s evaluations of Level I suppliers fell short of quality system requirements. The supplier self-audit questionnaire forms for two suppliers did not include answers to “pertinent quality system questions,” the letter notes.

Meanwhile, CareFusion’s supplier corrective actions don’t always demonstrate verification, the letter says. One was initiated for occlusion complaints for the Mask Air Entrainment Adult 50/CS, which is used as a flow selector with nebulizers. The devicemaker deemed it acceptable “despite the lack of documentation to verify the corrective actions,” the letter says, adding CareFusion’s response to this citation will also need to be verified during reinspection.

The company’s MDR procedure was cited for lacking instructions on obtaining and completing the FDA 3500A form, along with the address for submitting MDR reports.

The company’s Heated Ventilator & Anesthesia Breathing Circuit and Denver Ascites Shunt and Percutaneous Access Kit with Ascites (peritoneovenous) shunt were also found to be adulterated because of changes to device materials that were not followed up by new 510(k) applications. The letter tells CareFusion to stop distributing the devices.

CareFusion spokesman Toy Kirkpatrick said the company takes the letter seriously and has “invested significantly to strengthen our quality system and regulatory compliance and controls. He added that the firm has met with the FDA and received the go-ahead on plans to recommercialize the Denver shunts and transition customers from CareFusion’s heated breathing circuits to ones made by Fisher & Paykel.

Make sure your products are particle free! Avoid a warning letter and ensure that you’re producing sterile products, order Manufacturing Sterile Products to Meet EU and FDA Guidelines today!

Medical Devices Inspections and Audits Postmarket Safety

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing